EA202190891A1 - COMPOSITIONS AND METHODS FOR CONTROLLED OVARIAN STIMULATION - Google Patents

COMPOSITIONS AND METHODS FOR CONTROLLED OVARIAN STIMULATION

Info

Publication number
EA202190891A1
EA202190891A1 EA202190891A EA202190891A EA202190891A1 EA 202190891 A1 EA202190891 A1 EA 202190891A1 EA 202190891 A EA202190891 A EA 202190891A EA 202190891 A EA202190891 A EA 202190891A EA 202190891 A1 EA202190891 A1 EA 202190891A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
methods
ovarian stimulation
controlled ovarian
controlled
Prior art date
Application number
EA202190891A
Other languages
Russian (ru)
Inventor
Хоан-Карлес Арсе Саэс
Лисбет Хельмгор
Бьярке Мирнер Клейн
Патрик Хейзер
Original Assignee
Ферринг Бв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ферринг Бв filed Critical Ферринг Бв
Priority claimed from PCT/EP2019/078170 external-priority patent/WO2020079127A1/en
Publication of EA202190891A1 publication Critical patent/EA202190891A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Описаны способы применения и композиции, включающие FSH для применения для лечения бесплодия, где дозу выбирают на основании возраста пациента для оптимизации кумулятивной эффективности и/или снижения риска развития OHSS.Described are methods of use and compositions comprising FSH for use in the treatment of infertility, where the dose is selected based on the age of the patient to optimize the cumulative efficacy and / or reduce the risk of OHSS.

EA202190891A 2018-10-29 2019-10-17 COMPOSITIONS AND METHODS FOR CONTROLLED OVARIAN STIMULATION EA202190891A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18203167 2018-10-29
PCT/EP2019/078170 WO2020079127A1 (en) 2018-10-17 2019-10-17 Compositions and methods for controlled ovarian stimulation

Publications (1)

Publication Number Publication Date
EA202190891A1 true EA202190891A1 (en) 2021-07-12

Family

ID=64082983

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190891A EA202190891A1 (en) 2018-10-29 2019-10-17 COMPOSITIONS AND METHODS FOR CONTROLLED OVARIAN STIMULATION

Country Status (1)

Country Link
EA (1) EA202190891A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114936662A (en) * 2022-02-18 2022-08-23 北京大学第三医院（北京大学第三临床医学院） System for predicting ovarian hyperresponsiveness of subject

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114936662A (en) * 2022-02-18 2022-08-23 北京大学第三医院（北京大学第三临床医学院） System for predicting ovarian hyperresponsiveness of subject

Similar Documents

Publication Publication Date Title
CL2018001152A1 (en) Compositions and methods for cancer treatment
MX2023007212A (en) Epinephrine spray formulations.
EA201890009A1 (en) EZH2 INHIBITORS FOR TREATING LYMPHOMA
EA201891268A1 (en) COMPOUNDS WHICH CAN BE USED AS KINASE INHIBITORS
EA202191122A1 (en) SELECTIVE TO RGMc INHIBITORS AND THEIR APPLICATION
SA519410324B1 (en) Epinephrine spray formulations
PH12020550942A1 (en) Antimicrobial peptides and methods of using same
JOP20210245A1 (en) Methods of Treating AL Amyloidosis
MX2022006073A (en) Methods of use of anti-trem2 antibodies.
EA201892297A1 (en) METHODS FOR TREATING CHOLESTATIC AND FIBROTIC DISEASES
PH12021550122A1 (en) Solubilized apyrases, methods and use
NZ762312A (en) Anti-pacap antibody
CL2022000779A1 (en) Compositions and Methods for Controlled Ovarian Stimulation (Divisional Application No. 202100928)
EA202090266A1 (en) MPO INHIBITORS FOR MEDICAL USE
EA202190891A1 (en) COMPOSITIONS AND METHODS FOR CONTROLLED OVARIAN STIMULATION
EA202191058A1 (en) ANTIBODIES AGAINST MUCIN-16 AND METHODS OF THEIR APPLICATION
EA202190226A1 (en) METHODS FOR TREATMENT OF HFpEF USING DAPAGLIFLOSIN AND COMPOSITIONS CONTAINING IT
EA201992852A1 (en) DOSAGE DIAGRAM FOR TESETAXEL AND CAPETSITABINE
MX2021002444A (en) Compounds and methods for treating fungal infections.
EA202090480A1 (en) COMPOSITION FOR CONTROLLED OVARIAN STIMULATION
MX2021002647A (en) Methods of treating psoriasis.
EA202091802A1 (en) BEXAROTENE DERIVATIVES AND THEIR USE FOR CANCER TREATMENT
AR116734A1 (en) COMPOSITIONS AND METHODS FOR CONTROLLED OVARIAN STIMULATION
MX2016008272A (en) Methods of treating women for hypoactive sexual desire disorder (hsdd) with bupropion and trazodone combination treatment.
EA201990824A1 (en) ANTIBODIES THAT CONTACT INTERLEUKIN-2 AND THEIR APPLICATION